The last November BioSeed Capital with headquarters in the Parc Científic of Barcelona established a new office in London to get access to UK’s market, one of the most powerful worldwide in healthcare startups, as well as in pharmaceutical firms.

Juan R. García, CEO of BioSeed Capital, explains how he sees this new business opportunity: “We work in a global sector where innovation requires an international presence for its commercialization. London is one of the most important centers worldwide in innovation and access to capital. We are sure that installing our headquarters there will help us to develop our international networking”.

The United Kingdom is a global center of excellence in Life Sciences and is the third most popular investment location in the world. Over £5 billion has been invested in the high-tech industries from the UK. Some data shows that nearly 750 companies of medical biotechnology are based in the UK with a combined turnover of £4.2 billion, representing an estimated 30% of European turnover in the sector. Furthermore, within these companies, 86% are engaged in research and development, resulting in innovation.

On another side, the pharmaceutical sector consists of around 600 companies with annual sales of around £15.6 billion, including big pharma’s headquarters of GlaxoSmithKline and AstraZeneca and other foreign companies with major presence in the UK including Pfizer, Novartis and Hoffmann-La Roche.

All this added to its university’s research excellence makes the United Kingdom in an essential spot in Europe to look for new markets.

Latest news

The Biotechnology Business Institute closes the 5th edition of the Scientific MBA in Lifesciences with a great success and four projects developing drug candidates.

Four drug candidates targeting three indications, Breast Cancer, Chron’s Syndrome and NASH (nonalcoholic steatohepatitis), were presented by our students in the closing ceremony of the Scientific MBA’s as a result of a year developing different intellectual properties for potential new treatments

BBI Case Study in International Strategy. Aortyx, a success case in early stage funding for medical device focus in aortic disease

During the evening of the BBI Open Day a study case in early stage funding was presented by Jordi Martorell, Patrick O’Brien, Lifesciences consultant, and William Hariri, Director at Alira Health. The main objective of the evening was to understand how to develop and international strategy for medical devices.

The Biotechnology Business Institute closes the first BBI Open Day with great success inspiring young scientific professionals

The importance of scientific profiles in a society based in innovation and how their professional development in management can contribute to drug discovery, were some of the main topics presented during the BBI Open Day 2019

The first 2019 BioInternational Seminar is a success and gain interest between scientific profiles with vision in drug discovery

International experts shared their experience and knowledge in the pharmaceutical industry and the biotechnology sector over an evening with young scientific profiles developing their career in the drug discovery field

Filter by category